Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
unrelated Processed

Bain Capital & AbbVie

3 shared events · Importance 3 · Last updated May 20, 2025

Importance
3
Shared Events
3
Actions
0
Sentiment
-43.333333333333336
Live sentiment trends, interaction importance charts, and action volume tracking available on the NewsDesk Dashboard

Bain Capital does not have a direct structural or commercial relationship with AbbVie.

75
Business
Bain Capital: Bain Capital, as Coeptis Therapeutics Holdings' controlling shareholder, is accused of acquiring Coeptis Therapeutics Holdings shares at an artificially depressed price while allegedly possessing material nonpublic information about AbbVie Inc.'s acquisition interest, resulting in a significant windfall.
AbbVie: AbbVie Inc. is implicated in the lawsuit for its alleged undisclosed interest in acquiring Coeptis Therapeutics Holdings at a higher price than the secondary offering, which supposedly led to an artificially deflated stock price for Coeptis Therapeutics Holdings.
Apr 17, 2025 · 6 articles
75
Business
Bain Capital: Bain Capital, Coeptis Therapeutics Holdings's controlling shareholder, acquired shares at an allegedly artificially depressed price during the October Offering while in possession of material nonpublic information about AbbVie Inc.'s interest, leading to a $120 million windfall.
AbbVie: AbbVie Inc. agreed to acquire Coeptis Therapeutics Holdings for $45 per share, a price significantly higher than Coeptis Therapeutics Holdings's secondary offering price, which is central to the alleged securities fraud.
Apr 18, 2025 · 6 articles
73
Business
Bain Capital: Bain Capital, LP is accused of orchestrating a secondary stock offering of Coeptis Therapeutics Holdings at a deeply discounted price, allowing it to increase its position before the undisclosed acquisition by AbbVie Inc., resulting in a $120 million windfall.
AbbVie: AbbVie Inc. acquired Coeptis Therapeutics Holdings for $45 per share, an acquisition that was allegedly undisclosed during Coeptis Therapeutics Holdings's secondary stock offering, leading to a windfall for Bain Capital, LP.
Apr 18, 2025 · 6 articles
NEWSDESK
Explore this relationship live

Track how Bain Capital and AbbVie interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.